bioRxiv : the preprint server for biology
August 2, 2025
Belen Karakullukcu, Hamilton White, Christopher Connor et al.
preprint
Ketamine is a dissociative anesthetic used in subanesthetic doses with analgesic and anti-depressive properties. However, its mechanistic effects on neuronal signaling and circuit function remain underexplored. We address this shortcoming by employing multi-neuronal imaging in the simple nematode C. elegans that allows measurement of neuron activity across the animal's entire head with...
Cells
August 1, 2025
Armida Miranda-Riestra, Rosa Estrada-Reyes, Luis A Constantino-Jonapa et al.
Forty per cent of major depression patients are resistant to antidepressant medication. Thus, it is necessary to search for alternative treatments. Melatonin (N-acetyl-5-hydroxytryptamine) enhances neurogenesis and neuronal survival in the adult mouse hippocampal dentate gyrus. Additionally, melatonin stimulates the activity of Ca2+/Calmodulin-dependent Kinase II (CaMKII), promoting dendrite...
The International Journal of Neuropsychopharmacology
August 1, 2025
Paul Glue
Abstract Background Ketamine, a rapidly acting antidepressant, requires dosing in clinic because of strong symptoms of dissociation and sedation after IV/IN dosing. This need for dosing in clinic limits capacity to treat patients with Treatment Resistant depression (TRD). We hypothesize that ketamine formulations that maximize ketamine’s first pass metabolism and delay absorption will have...
The International Journal of Neuropsychopharmacology
August 1, 2025
P.-C. Wu, W. Lin, T.-P. Su et al.
Abstract Background As accumulating evidence suggests ketamine's antisuicidal properties, there has been growing interest in elucidating its underlying mechanisms and predictive factors for treatment response. However, the predictive power of several demographic and clinical characteristics varied across previous studies. Additionally, some potential predictors, such as baseline depression...
L'Encephale
August 1, 2025
Yara Bachir, Raymond Kassab, C. Hallal et al.
OBJECTIVE This case report explores the efficacy of intravenous Ketamine in treating active suicidal ideation in a 24-year-old female with comorbid major depressive disorder (MDD), borderline personality disorder (BPD), posttraumatic stress disorder (PTSD), and functional neurological disorder (FND). CASE DESCRIPTION The patient, with a history of multiple suicide attempts and...
American Journal of Geriatric Psychiatry
August 1, 2025
Ronesh Sukhdeo, Jocelyn K. Tamura, Christine E. Dri et al.
Ketamine has emerged as a promising treatment for major depression, though its efficacy and safety remain incompletely characterized in older adults. This systematic review synthesizes current evidence for ketamine in geriatric depression. A search of PubMed, EMBASE, and PsycINFO was conducted. Prospective clinical trials were included, with age restriction to participants ≥60 years applied at...
BMJ Open
August 1, 2025
Nicky J. Mehtani, B. Anderson, Irina Alexander et al.
INTRODUCTION: Methamphetamine use disorder (MeUD) is a debilitating condition with no FDA-approved pharmacotherapies that has been associated with poor neurological, psychiatric and cardiovascular outcomes, particularly among low-income populations. The use of methamphetamine also increases risks for sexually transmitted infections (STIs) by reducing behavioural inhibitions while enhancing...
International Journal of Molecular Sciences
August 1, 2025
Łukasz P. Szałach, Klaudia Ciesielska-Figlon, A. Daca et al.
7 citations
Treatment-resistant depression (TRD) is associated with immune dysregulation. Ketamine, a rapid-acting antidepressant, may exert effects via immunomodulation. The aim was to examine ketamine’s impact on immune markers in TRD, including T-cell subsets, cytokines, and in vitro T-cell responses. Eighteen TRD inpatients received 0.5 mg/kg iv ketamine. Blood was sampled at baseline, 4 h, and 24 h to...
Psychedelic Medicine
August 1, 2025
Kush V. Bhatt, Jason Compton, Em Ellerman et al.
1 citation
Mystical experiences are powerful experiences that may have therapeutic value. Ketamine, a dissociative anesthetic, has shown potential to induce mystical experiences. However, little research has explored this phenomenon, particularly in treatment-resistant depression. We analyzed clinical data from 60 veterans with treatment-resistant depression receiving a total of 189 ketamine treatments....
Cureus
August 1, 2025
Brett Hughes, Soz Mirza, Manasi Ponamala et al.
The stresses of the Coronavirus Disease of 2019 (COVID-19) pandemic highlighted the burden of psychiatric disorders within the pediatric population, revealing a pre-existing need for rapid-onset therapies that have since driven efforts to expand effective therapeutic interventions. In this narrative review, we utilized the Preferred Reporting Items for Systematic reviews and Meta-Analysis...